Emerson Provides 2025 Outlook: Sees Net Sales Growth Of 3.5% - 5.5%; Adj. EPS Of $5.85 - $6.05 Vs. $5.48 Est.
Emerson Provides 2025 Outlook: Sees Net Sales Growth Of 3.5% - 5.5%; Adj. EPS Of $5.85 - $6.05 Vs. $5.48 Est.
爱默生提供2025年展望：预计净销售增长3.5％-5.5％；调整后每股收益为5.85美元至6.05美元，预估值为5.48美元。
The following tables summarize the fiscal year 2025 guidance framework and does not include any impact from the proposed portfolio transactions announced today. The 2025 outlook assumes approximately $1.2 billion of dividend payments. Guidance figures are approximate.
以下表格总结了2025财政年度指导框架，不包括今天宣布的拟议投资组合交易的任何影响。2025年前景假设约12亿美元的股息支付。指导数据为近似值。
| 2025 Q1 | 2025 | |
| Net Sales Growth | 2.5% - 3.5% | 3.5% - 5.5% |
| Underlying Sales Growth | 2% - 3% | 3% - 5% |
| Earnings Per Share | $0.89 - $0.94 | $4.42 - $4.62 |
| Amortization of Intangibles | ~$0.31 | ~$1.23 |
| Restructuring / Related Costs | ~$0.04 | ~$0.16 |
| Acquisition / Divestiture Fees and Related Costs | ~$0.01 | ~$0.04 |
| Adjusted Earnings Per Share | $1.25 - $1.30 | $5.85 - $6.05 |
| Operating Cash Flow | $3.6B - $3.7B | |
| Free Cash Flow | $3.2B - $3.3B | |
| Share Repurchase | ~$1.0B | ~$2.0B |
| 2025年第一季度 | 2025 | |
| 净销售增长率 | 2.5% - 3.5% | 3.5% - 5.5% |
| 基础销售增长 | 2% - 3% | 3% - 5% |
| 每股收益 | $0.89 - $0.94 | $4.42 - $4.62 |
| 无形资产的摊销费用 | ~$0.31 | ~$1.23 |
| Restructuring / Related Costs | ~$0.04 | ~$0.16 |
| 收购/出售费用和相关成本 | ~$0.01 | ~$0.04 |
| 调整后的每股收益 | $1.25 - $1.30 | $5.85 - $6.05 |
| 经营性现金流 | 36亿美元 - 3.7亿美元 | |
| 自由现金流 | 32亿美元 - 3.3亿美元 | |
| 在该次发行和回购中的股份数 | 约1.0亿美元 | 约2.0亿美元 |
资讯热榜
更新时间